• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.

作者信息

Smyth Elizabeth, Glavey Siobhan, Melotti Dario, Thornton Patrick, Sargent Jeremy, Conlon Peter, Murphy Philip, Quinn John

机构信息

Department of Haematology, Beaumont Hospital, Dublin 9, Beaumont, Ireland.

Department of Nephrology, Beaumont Hospital, Dublin 9, Beaumont, Ireland.

出版信息

Ir J Med Sci. 2019 Aug;188(3):1079-1080. doi: 10.1007/s11845-018-1951-6. Epub 2018 Dec 19.

DOI:10.1007/s11845-018-1951-6
PMID:30569372
Abstract
摘要

相似文献

1
Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.在难治性骨髓瘤合并肾衰竭患者中，单药达雷妥尤单抗治疗后实现透析独立
Ir J Med Sci. 2019 Aug;188(3):1079-1080. doi: 10.1007/s11845-018-1951-6. Epub 2018 Dec 19.
2
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.单药达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的真实世界回顾性单中心研究。
Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.
3
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤患者后的免疫调节剂药物和蛋白酶体抑制剂再治疗的疗效。
Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.
4
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.针对来那度胺和硼替佐米耐药的多发性骨髓瘤患者，CD38 靶向免疫化疗的治疗潜力的临床前证据。
Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.
5
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
6
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.免疫疗法：一种使用达雷木单抗和埃罗妥珠单抗治疗多发性骨髓瘤的新方法。
Ann Pharmacother. 2016 Jul;50(7):555-68. doi: 10.1177/1060028016642786. Epub 2016 Apr 15.
7
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.新型单克隆抗体治疗复发/难治性多发性骨髓瘤疗效与安全性的系统评价和荟萃分析
Oncotarget. 2017 May 16;8(20):34001-34017. doi: 10.18632/oncotarget.16987.
8
Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.达雷妥尤单抗为基础的三联疗法治疗复发或难治性多发性骨髓瘤患者的成本效益分析。
Clin Ther. 2018 Jul;40(7):1122-1139. doi: 10.1016/j.clinthera.2018.05.012. Epub 2018 Jul 11.
9
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.在美国复发或难治性多发性骨髓瘤患者中实施达雷妥尤单抗早期准入治疗方案的结果。
Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.
10
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.单药达雷妥尤单抗治疗晚期多发性骨髓瘤，即便在未经筛选的“真实世界”人群中也具有显著疗效。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6.

引用本文的文献

1
Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis.基于抗CD38单克隆抗体的免疫疗法在伴有肾功能不全的多发性骨髓瘤中的评估：一项系统评价和荟萃分析。
Ther Adv Hematol. 2025 Feb 17;16:20406207251319593. doi: 10.1177/20406207251319593. eCollection 2025.
2
Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.利用微小残留病灶作为结直肠癌预测指标：挑战与希望并存。
Medicina (Kaunas). 2023 Oct 23;59(10):1886. doi: 10.3390/medicina59101886.
3
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.

本文引用的文献

1
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.达雷妥尤单抗在多发性骨髓瘤继发的透析依赖型肾衰竭中的安全性和有效性。
Haematologica. 2018 Jun;103(6):e277-e278. doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.
2
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.泊马度胺联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤伴肾功能损害患者的疗效：一项 II 期试验结果。
J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.
3
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.
达雷妥尤单抗的临床药代动力学和药效学。
Clin Pharmacokinet. 2023 Jun;62(6):789-806. doi: 10.1007/s40262-023-01240-8. Epub 2023 May 2.
4
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.先进疗法时代复发难治性多发性骨髓瘤的管理：基于证据的常规临床实践建议
Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.
5
Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.复发/难治性多发性骨髓瘤：可用疗法综述及骨髓瘤复发时的临床情况。
Curr Oncol. 2023 Feb 15;30(2):2322-2347. doi: 10.3390/curroncol30020179.
6
Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits.免疫调节药物联合地塞米松治疗单克隆免疫球蛋白沉积性增殖性肾小球肾炎的疗效
Kidney Int Rep. 2022 Aug 8;7(10):2166-2175. doi: 10.1016/j.ekir.2022.07.009. eCollection 2022 Oct.
7
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.复发/难治性多发性骨髓瘤合并肾功能损害患者的治疗选择概述
Ther Adv Hematol. 2022 Apr 2;13:20406207221088458. doi: 10.1177/20406207221088458. eCollection 2022.
8
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗新诊断的依赖透析的多发性骨髓瘤患者后的肾脏恢复情况
CEN Case Rep. 2022 May;11(2):265-268. doi: 10.1007/s13730-021-00668-w. Epub 2021 Nov 24.
9
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.依鲁替尼联合卡非佐米和地塞米松与卡非佐米和地塞米松治疗伴有肾功能损害的复发多发性骨髓瘤患者：IKEMA 亚组分析。
Haematologica. 2022 Jun 1;107(6):1397-1409. doi: 10.3324/haematol.2021.279229.
10
Daratumumab in dialysis-dependent multiple myeloma.达雷妥尤单抗用于透析依赖型多发性骨髓瘤
Blood Res. 2020 Mar;55(1):65-67. doi: 10.5045/br.2020.55.1.65. Epub 2020 Mar 30.
新诊断的需要透析的骨髓瘤患者的预后：肾脏恢复、快速反应的重要性及生存获益
Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49.
4
A population-based study of the impact of dialysis on mortality in multiple myeloma.一项基于人群的关于透析对多发性骨髓瘤死亡率影响的研究。
Br J Haematol. 2018 Feb;180(4):588-591. doi: 10.1111/bjh.14394. Epub 2016 Oct 21.
5
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
6
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.多发性骨髓瘤患者在从依赖透析的急性肾损伤中恢复后，具有出色的长期预后。
Eur J Haematol. 2016 Jun;96(6):610-7. doi: 10.1111/ejh.12644. Epub 2015 Sep 16.
7
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.血清游离轻链的早期降低与骨髓瘤肾的肾功能恢复相关。
J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.
8
Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.严重急性肾损伤和多发性骨髓瘤患者的表现和生存：单中心 20 年经验。
Nephrol Dial Transplant. 2010 Feb;25(2):419-26. doi: 10.1093/ndt/gfp488. Epub 2009 Sep 19.
9
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.硼替佐米对晚期肾衰竭多发性骨髓瘤患者的活性及安全性：一项多中心回顾性研究
Blood. 2007 Mar 15;109(6):2604-6. doi: 10.1182/blood-2006-09-046409. Epub 2006 Nov 30.